A federal jury awarded Insulet Corp. $452 million against Eoflow Co. Ltd., concluding that Eoflow and other defendants stole ...
A ketone body, a molecule derived from the metabolism of acids to obtain energy when glucose is not available, could become ...
Merus NV gained accelerated U.S. FDA approval of Bizengri (zenocutuzumab) as the first and only targeted therapy indicated for NRG1-positive pancreatic adenocarcinoma and non-small-cell lung cancer ...
Spur Therapeutics Ltd. has selected SPR-301 as lead development candidate from its gene therapy program for a genetically ...
Methods that may work well for recruiting and retaining white patients for clinical trials may need to be adjusted to ...
In breast cancer, neoadjuvant chemotherapy reduces the tumor before surgery. However, the response to this treatment does not ...
Beacon Biosignals Inc. can rest easy now that it has received U.S. FDA authorization of its predetermined change control plan ...
Eli Lilly and Co.’s weight-loss drug Zepbound (tirzepatide) made headlines yet again as the Indianapolis-based firm disclosed top-line data from the Surmount-5 phase IIIb study. The open-label, ...
Eterna Therapeutics Inc. has announced plans to evaluate the ability of ERNA-101 to induce and modulate antitumor immunity in ovarian cancer and breast cancer models through a sponsored research ...
Kinnate Biopharma Inc. and affiliated organizations recently reported preclinical data for the novel brain-penetrant combination therapy using the MEK inhibitor KIN-7136 and the RAF inhibitor KIN-8391 ...
Researchers from Suzhou Siran Biotech Co. Ltd. presented the discovery and preclinical characterization of SA-1211, an N-acetylgalactosamine (GalNAc)-conjugated siRNA dimer targeting both hepatitis B ...
Data from a preclinical study assessing Mission Therapeutics Ltd.’s clinical-stage USP30 inhibitor MTX-652, for the prevention of transverse aortic constriction (TAC)-induced cardiac hypertrophy and ...